NCT03300674

Brief Summary

This is a randomized, double-blind, emergency department based, comparative effectiveness study of two medication for acute abdominal pain: intravenous lidocaine and intravenous hydromorphone. Patients will be enrolled during an emergency department visit and followed throughout their emergency department course and then by telephone 7 days later.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
154

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jan 2018

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 28, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 3, 2017

Completed
3 months until next milestone

Study Start

First participant enrolled

January 10, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 16, 2018

Completed
12 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 28, 2018

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

November 26, 2019

Completed
Last Updated

August 10, 2020

Status Verified

July 1, 2020

Enrollment Period

7 months

First QC Date

September 28, 2017

Results QC Date

November 7, 2019

Last Update Submit

July 29, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in 0-10 Pain Scale Between Baseline and 90 Minutes

    Participants were asked to describe their pain on a scale from 0 to 10 with 0= no pain and 10= the worst pain imaginable

    up to 90 minutes

Secondary Outcomes (2)

  • Rescue Medication

    4 hours

  • Adverse Events

    4 hours

Study Arms (2)

Intravenous hydromorphone

ACTIVE COMPARATOR

Intravenous hydromorphone 1mg. A second dose can be administered at 30 minutes.

Drug: Hydromorphone

Intravenous lidocaine

ACTIVE COMPARATOR

Intravenous lidocaine 120 mg. A second dose can be administered at 30 minutes

Drug: Lidocaine

Interventions

Hydromorphone intravenous infusion

Intravenous hydromorphone

Lidocaine intravenous infusion

Intravenous lidocaine

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Montefiore Medical Center

The Bronx, New York, 10467, United States

Location

Related Publications (1)

  • Chinn E, Friedman BW, Naeem F, Irizarry E, Afrifa F, Zias E, Jones MP, Pearlman S, Chertoff A, Wollowitz A, Gallagher EJ. Randomized Trial of Intravenous Lidocaine Versus Hydromorphone for Acute Abdominal Pain in the Emergency Department. Ann Emerg Med. 2019 Aug;74(2):233-240. doi: 10.1016/j.annemergmed.2019.01.021. Epub 2019 Feb 26.

MeSH Terms

Conditions

Abdominal Pain

Interventions

HydromorphoneLidocaine

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsSigns and Symptoms, Digestive

Intervention Hierarchy (Ancestors)

Morphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsAcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Results Point of Contact

Title
Benjamin W. Friedman
Organization
Montefiore

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Double-blind
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 28, 2017

First Posted

October 3, 2017

Study Start

January 10, 2018

Primary Completion

August 16, 2018

Study Completion

August 28, 2018

Last Updated

August 10, 2020

Results First Posted

November 26, 2019

Record last verified: 2020-07

Data Sharing

IPD Sharing
Will not share

Locations